Panel Discussion: Building Strategic Collaborations & Investment Pathways to Accelerate RNA-Targeted Drug Discovery Across Biotech & Pharma

Time: 8:45 am
day: Conference Day Two

Details:

• Discussing the importance of pharma-biotech-academic collaborations and what each sector can provide to successfully create RNA-targeted therapeutics

• How are large pharma and biotech companies structuring risk-sharing partnerships to access innovation and accelerate RNA-targeted therapeutic pipelines

• How can early-stage companies leverage academic collaborations, tool compound sharing and co development deals to validate targets and attract strategic capital

• What trends can be identified from recent investments, M&A activity and deal structures to inform future strategies in RNA therapeutics

Speakers:

Peng Yue
Peng Yue A computational biologist with a strong interest in improving human health through engineering drug discovery process. Over 18 years of hands-on biotech experience specializing in Read more
Elena Diez Cecilia
Elena Diez Cecilia Elena is Senior Director of External Innovation within Discovery, Product Development & Supply (DPDS) at Janssen R&D and part of the J&J Innovation East North Read more
Jerry McMahon
Jerry McMahon Jerry has over 30 years of biotechnology leadership, scientific innovation, creative deal-making, and financing experience. With broad disease-area expertise and a specialty in oncology therapeutics, Read more
Nikolai Naryshkin
Nikolai Naryshkin Nikolai Naryshkin is Chief Scientific Officer at Ribonaut Therapeutics. He has 20+ years of experience in targeting RNA with small molecules and nucleic acid derived Read more
Jennifer Petter
Jennifer Petter Jennifer Petter, Ph.D., is a Founder & Chief Scientific Officer of Arrakis Therapeutics. An experienced drug hunter, scientist, and life science executive, Dr. Petter’s research Read more
Atsushi Shiomi
Atsushi Shiomi Atsushi Shiomi, Ph.D., Japanese Patent Attorney, is Director of Innovation Research Partnering at NS Pharma. Trained in medicinal chemistry with a doctorate in Pharmaceutical Sciences, Read more
Christopher O’Donnell
Christopher O’Donnell Christopher O’Donnell, PHD is a Partner at Pfizer Ventures and Vice President, Worldwide Business Development. Chris is responsible for identifying, evaluating, making and managing equity Read more